Pulse Biosciences: Cash Flow Bleed Remains A Concern Ahead Of 2024 Catalysts [Seeking Alpha]
Pulse Biosciences, Inc (PLSE)
Last pulse biosciences, inc earnings: 11/7 03:42 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.pulsebiosciences.com
Company Research
Source: Seeking Alpha
The company's nanosecond pulsed field ablation technology is seen as superior to existing cardiac surgical tools on the market. While the product potential is encouraging, we highlight a recurring negative cash flow that may keep shares under pressure. Looking for more investing ideas like this one? Get them exclusively at Conviction Dossier. Learn More » Pulse Biosciences Inc. ( NASDAQ: PLSE ) specializes in technology for the treatment of atrial fibrillation (AF), a cardiovascular disorder defined by irregular heartbeats often associated with high blood pressure and heart valve disease. The idea here is the potential for the company's nanosecond pulsed field ablation ((nsPFA)) devices to revolutionize cardiology through clinical advantages compared to current surgical standards. The good news is that Pulse is moving forward with an FDA submission for an expected clearance of its nsPFA cardiac surgical clamp by Q1 2024. The company also expects to commence clinical trials
Show less
Read more
Impact Snapshot
Event Time:
PLSE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLSE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLSE alerts
High impacting Pulse Biosciences, Inc news events
Weekly update
A roundup of the hottest topics
PLSE
News
- Pulse Biosciences (PLSE): Valuation Check After FDA IDE Approval for nPulse Cardiac Ablation Trial [Yahoo! Finance]Yahoo! Finance
- Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial [Yahoo! Finance]Yahoo! Finance
- Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation [Yahoo! Finance]Yahoo! Finance
- Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial FibrillationBusiness Wire
PLSE
Earnings
- 11/5/25 - Beat
PLSE
Sec Filings
- 12/18/25 - Form 8-K
- 12/12/25 - Form 8-K
- 12/9/25 - Form 8-K
- PLSE's page on the SEC website